Copyright
©The Author(s) 2015.
World J Gastroenterol. Mar 21, 2015; 21(11): 3282-3290
Published online Mar 21, 2015. doi: 10.3748/wjg.v21.i11.3282
Published online Mar 21, 2015. doi: 10.3748/wjg.v21.i11.3282
Figure 1 Cumulative probability of continuing infliximab or adalimumab therapy during follow-up.
The dashes represent patients who remained on therapy during the follow-up and mark their individual end of follow-up. IFX: Infliximab; ADA: Adalimumab.
- Citation: Baki E, Zwickel P, Zawierucha A, Ehehalt R, Gotthardt D, Stremmel W, Gauss A. Real-life outcome of anti-tumor necrosis factor α in the ambulatory treatment of ulcerative colitis. World J Gastroenterol 2015; 21(11): 3282-3290
- URL: https://www.wjgnet.com/1007-9327/full/v21/i11/3282.htm
- DOI: https://dx.doi.org/10.3748/wjg.v21.i11.3282